Progress in research of safety, efficiency and vaccination status of influenza vaccine in populations at high risk.
10.3760/cma.j.cn112338-20210227-00153
- Author:
Hai Tian SUI
1
;
Yang GUO
1
;
Jie ZHAO
1
;
Zhong Nan YANG
1
;
Jin Feng SU
1
;
Yuan YANG
2
;
Qing WANG
3
;
Lu Zhao FENG
3
Author Information
1. China National Biotec Group Company Limited, Beijing 100024, China.
2. Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
3. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Review
- MeSH:
China;
Costs and Cost Analysis;
Humans;
Influenza Vaccines/adverse effects*;
Influenza, Human/prevention & control*;
Vaccination
- From:
Chinese Journal of Epidemiology
2022;43(3):436-439
- CountryChina
- Language:Chinese
-
Abstract:
This paper reviews the domestic and foreign studies published in 2020 on the application of influenza vaccine in populations at high risk. The importance of influenza vaccination in population at high risk has been proved by larger sample, multicentre, high-quality evidence-based studies. Influenza vaccination is the most cost-effective measure to prevent influenza. However, the coverage rate of influenza vaccine is very low in China, it is necessary to strengthen the health education to promote influenza vaccination in different populations. It is recommended to give influenza vaccination to the population in whom influenza vaccination has been proven safe and effective before influenza season. Research of the safety, efficiency and cost-effectiveness of influenza vaccine should be accelerated for the populations in whom such data are lacking or insufficient.
